ASTELLAS PHARMA INC./ JP3942400007 /
07/11/2024 21:44:20 | Chg. +0.065 | Volume | Bid07/11/2024 | Demandez à07/11/2024 | Capitalisation boursière | Dividende Y. | Rapport P/E |
---|---|---|---|---|---|---|---|
10.490EUR | +0.62% | 93 Chiffrre d'affaires: 971 |
10.355Bid taille: 240 | 10.500Ask la taille: 240 | 18.94 Mrd.EUR | - | - |
GlobeNewswire
14/08
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire
08/08
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
GlobeNewswire
16/04
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
19/03
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degene...
GlobeNewswire
26/02
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
07/02
LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veter...
GlobeNewswire
11/12/2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
19/10/2023
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
14/09/2023
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daph...
GlobeNewswire
11/09/2023
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page